PMID- 33204726
OWN - NLM
STAT- MEDLINE
DCOM- 20210317
LR  - 20220418
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2020
DP  - 2020
TI  - Is Lutikizumab, an Anti-Interleukin-1alpha/beta Dual Variable Domain Immunoglobulin, 
      efficacious for Osteoarthritis? Results from a bayesian network meta-analysis.
PG  - 9013283
LID - 10.1155/2020/9013283 [doi]
LID - 9013283
AB  - OBJECTIVE: Most guidelines recommend the use of nonsteroidal anti-inflammatory 
      drugs (NSAIDs), duloxetine, and tramadol for the nonoperative treatment of 
      osteoarthritis (OA), but the use of them is limited by the tolerability and 
      safety concerns. Lutikizumab is a novel anti-IL-1alpha/beta dual variable domain 
      immunoglobulin that can simultaneously bind and inhibit IL-1alpha and IL-1beta to 
      relieve the pain and dysfunction symptoms. We conducted this network 
      meta-analysis to comprehensively compare the clinical efficacy and safety of 
      lutikizumab with other drugs recommended by guidelines. METHODS: We conducted a 
      Bayesian network and conventional meta-analyses to compare the efficacy and 
      safety of lutikizumab with other traditional drugs. All eligible randomized 
      clinical trials, in PubMed, CNKI, EMBASE, and Web of Science databases, from 
      January 2000 to January 2020, were included. The Cochrane risk of the bias 
      assessment tool was used for quality assessment. Pain relief, function 
      improvement, and risk of adverse effects (AEs) were compared in this study. 
      RESULTS: 24 articles with 11858 patients were included. Duloxetine (DUL) had the 
      largest effect for pain relief (4.76, 95% CI [2.35 to 7.17]), and selective cox-2 
      inhibitors (SCI) were the most efficacious treatment for physical function 
      improvement (SMD 3.94, 95% CI [2.48 to 5.40]). Lutikizumab showed no benefit 
      compared with placebo for both pain relief (SMD 1.11, 95% CI [-2.29 to 4.52]) and 
      function improvement (SMD 0.992, 95% CI [-0.433 to 4.25]). Lutikizumab and all 
      other drugs are of favorable tolerance for patients in the treatment of OA 
      compared with placebo. CONCLUSIONS: Lutikizumab, the new anti-Interleukin-1alpha/beta 
      dual variable domain immunoglobulin, showed no improvement in pain or function 
      when compared with placebo. Selective cox-2 inhibitors and duloxetine remain the 
      most effective and safest treatment for OA. More high-quality trials are still 
      needed to reconfirm the findings of this study.
CI  - Copyright (c) 2020 Ziqin Cao et al.
FAU - Cao, Ziqin
AU  - Cao Z
AUID- ORCID: 0000-0002-2465-5701
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Li, Yajia
AU  - Li Y
AUID- ORCID: 0000-0003-4710-087X
AD  - Department of Dermatology, Xiangya Hospital, Central South University, Changsha, 
      China.
FAU - Wang, Wanchun
AU  - Wang W
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Jie, Shuo
AU  - Jie S
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Hu, Xuantao
AU  - Hu X
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Zhou, Jian
AU  - Zhou J
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Wu, Tong
AU  - Wu T
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Aili, Dilihumaer
AU  - Aili D
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Long, Zeling
AU  - Long Z
AD  - Department of Orthopedic Surgery, Mayo Clinic Rochester, USA.
FAU - Li, Yihan
AU  - Li Y
AD  - Department of Orthopedic Surgery, University of California, Davis Medical Center, 
      USA.
FAU - Dou, Pengcheng
AU  - Dou P
AUID- ORCID: 0000-0003-3719-4040
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
FAU - Wu, Ren
AU  - Wu R
AUID- ORCID: 0000-0002-4128-2257
AD  - Department of Orthopedics, The Second Xiangya Hospital, Central South University, 
      Changsha, Hunan 410011, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20201104
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (IL1A protein, human)
RN  - 0 (IL1B protein, human)
RN  - 0 (Immunoglobulins)
RN  - 0 (Interleukin-1alpha)
RN  - 0 (Interleukin-1beta)
RN  - 15FAZ725S0 (lutikizumab)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
MH  - Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacology/*therapeutic 
      use
MH  - Bayes Theorem
MH  - Celecoxib/therapeutic use
MH  - Cyclooxygenase 2 Inhibitors/adverse effects/therapeutic use
MH  - Humans
MH  - Immunoglobulins/adverse effects/pharmacology/*therapeutic use
MH  - Interleukin-1alpha/antagonists & inhibitors
MH  - Interleukin-1beta/antagonists & inhibitors
MH  - Osteoarthritis/*drug therapy
MH  - Pain/drug therapy/etiology
MH  - Treatment Outcome
PMC - PMC7661137
COIS- The authors declare that they do not have any competing interests.
EDAT- 2020/11/19 06:00
MHDA- 2021/03/18 06:00
PMCR- 2020/11/04
CRDT- 2020/11/18 06:00
PHST- 2020/05/31 00:00 [received]
PHST- 2020/09/20 00:00 [revised]
PHST- 2020/10/09 00:00 [accepted]
PHST- 2020/11/18 06:00 [entrez]
PHST- 2020/11/19 06:00 [pubmed]
PHST- 2021/03/18 06:00 [medline]
PHST- 2020/11/04 00:00 [pmc-release]
AID - 10.1155/2020/9013283 [doi]
PST - epublish
SO  - Biomed Res Int. 2020 Nov 4;2020:9013283. doi: 10.1155/2020/9013283. eCollection 
      2020.